Prot# EMR 62 225-030: An Open-Label, Multicenter, Multinational Phase III Follow-up Study to Investigate the Long-Term Safety & Efficacy of Sarizotan HCl 1mg b.i.d. in Patients w/Parkinson's Disease Suffering from Treatment-Associated Dyskinesia

Project: Research project

Project Details

Effective start/end date8/5/057/31/08


  • Monitoring Force USA, Inc. (EMR 62 225-030)
  • Merck KGaA (EMR 62 225-030)